XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments (Tables)
 3 Months Ended
Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Schedule of purchase warrants outstanding

A summary of the status of the Company’s outstanding share purchase warrants is presented below:

 

        Number of Shares       Weighted Average Exercise Price   
Balance, October 1, 2017        1,609,309     $ 2.66  
Issued       350,000     $ 4.19  
Exercised       (756,143 )   $ 2.96  
Expired       (524,787 )   $ 3.00  
                   
Balance, September 30, 2018 and December 31, 2018       678,379     $ 2.87  
Schedule of exercisable share purchase warrants outstanding

At December 31, 2018, the Company had share purchase warrants outstanding of 678,379, with a weighted average exercise price of $2.87 as follows:

 

Number     Exercise Price     Expiry Date
30,000     $ 4.00     February 24, 2019
277,127     $ 1.20     March 13, 2019
1,252     $ 1.68     March 13, 2019
12,500     $ 1.24     May 31, 2019
7,500     $ 1.04     May 31, 2019
350,000     $ 4.19     June 30, 2021
678,379              
Schedule of outstanding stock purchase options

A summary of the status of Company’s outstanding stock purchase options is presented below: 

 

      Number of Shares     Weighted Average Exercise Price     Weighted Average Grant Date Fair Value  
Outstanding at October 1, 2017       5,092,030     $ 4.13          
Granted       1,730,000     $ 2.71       $ 2.09  
Forfeited       (164,280 )   $ 3.66          
Exercised       (150,833 )   $ 1.18          
Outstanding at September 30, 2018       6,506,917     $ 3.83          
Granted       855,399     $ 2.58       $ 2.07  
Forfeited       (163,550 )   $ 2.55          
Outstanding at December 31, 2018       7,198,766     $ 3.71          
Exercisable at December 31, 2018       4,359,159     $ 3.84          
Schedule of stock options outstanding

At December 31, 2018, the following stock options were outstanding:

 

Number of Shares                        
Total     Number
Vested		     Exercise
Price		     Expiry Date   Aggregate
Intrinsic
Value		     Remaining
Contractual
Life (yrs)		  
  500,000       500,000     $ 1.60     July 5, 2023   $ —       4.51  
  37,500       37,500     $ 1.20     May 7, 2024     13,500       5.35  
  125,000       125,000     $ 1.32     May 8, 2024     30,000       5.35  
  618,750       618,750     $ 0.92     April 2, 2025     396,000       6.25  
  29,167       29,167     $ 1.44     June 8, 2025     3,500       6.44  
  50,000       50,000     $ 1.76     June 15, 2025     —       6.46  
  253,750       253,750     $ 5.04     September 18, 2025     —       6.72  
  1,500       1,500     $ 5.64     September 30, 2025     —       6.75  
  31,250       31,250     $ 5.68     October 2, 2025     —       6.75  
  25,000       25,000     $ 8.98     October 16, 2025     —       6.79  
  1,500       1,500     $ 5.57     December 31, 2025     —       7.00  
  1,500       1,500     $ 4.90     March 31, 2026     —       7.25  
  1,500       1,500     $ 5.66     April 27, 2026     —       7.32  
  1,500       1,500     $ 6.11     June 30, 2026     —       7.50  
  379,625       284,719     $ 6.26     July 5, 2026     —       7.51  
  861,429       646,072     $ 7.06     July 18, 2026     —       7.55  
  906,696       906,696     $ 3.28     September 22, 2026     —       7.73  
  60,000       45,000     $ 3.63     October 3, 2026     —       7.76  
  50,000       16,667     $ 5.39     February 7, 2027     —       8.10  
  40,000       26,666     $ 5.26     February 17, 2027     —       8.13  
  770,000       449,172     $ 5.92     May 12, 2027     —       8.36  
  12,500       6,250     $ 3.42     August 9, 2027     —       8.61  
  15,000       7,500     $ 4.33     September 19, 2027     —       8.72  
  540,000       180,000     $ 3.30     December 13, 2027     —       8.95  
  50,000       —     $ 2.60     March 2, 2028     —       9.17  
  200,000       50,000     $ 2.72     March 19, 2028     —       9.22  
  657,500       37,500     $ 2.30     May 15, 2028     —       9.37  
  150,000       25,000     $ 2.70     August 6, 2028     —       9.60  
  828,099       —     $ 2.58     October 1, 2028     —       9.75  
  7,198,766       4,359,159                 $ 443,000          
Schedule of general and administrative expenses and research and development expenses

These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows:

 

    2018     2017  
General and administrative   $ 1,055,588     $ 571,363  
Research and development     1,011,399       550,622  
Total share based compensation   $ 2,066,987     $ 1,121,985  
Schedule of weighted average assumptions for fair value of each option award

The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions:

 

    2018     2017  
Risk-free interest rate     2.96 %     2.26 %
Expected life of options (years)     5.45       6.60  
Annualized volatility     106.15 %     112.27 %
Dividend rate     0.00 %     0.00 %